Last updated: February 19, 2026
Summary: Peru patent PE20141585, granted on August 22, 2014, to Laboratorios Bagó S.A. and assigned to Laboratorios Bagó S.A., claims a pharmaceutical composition containing a fixed-dose combination of dapagliflozin and metformin hydrochloride. The patent's scope encompasses various pharmaceutical formulations and methods of treating type 2 diabetes mellitus. This analysis examines the patent's core claims, the asserted therapeutic uses, and its position within the broader competitive landscape, considering potential market entry of generic competitors and ongoing patent challenges.
What is the Scope of Patent PE20141585?
Patent PE20141585 defines a pharmaceutical composition comprising a specific dual-action therapeutic approach for managing type 2 diabetes. The core innovation lies in the synergistic combination of two distinct drug classes.
The patent claims cover:
- The Pharmaceutical Composition: The primary claim is for a pharmaceutical composition containing dapagliflozin and metformin hydrochloride. Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, while metformin hydrochloride is a biguanide, a commonly used first-line treatment for type 2 diabetes.
- Dosage Forms: The patent encompasses various pharmaceutical formulations of this combination, including but not limited to tablets, capsules, and oral suspensions. This broadens the applicability of the patent beyond a single product to include different methods of drug delivery.
- Therapeutic Use: The composition is claimed for the treatment of type 2 diabetes mellitus. This explicitly defines the intended medical application of the patented drug.
- Methods of Treatment: The patent also includes claims for methods of treating type 2 diabetes mellitus by administering the claimed pharmaceutical composition. This covers the practical application of the drug in a clinical setting.
- Specific Dosing Regimens: While not always explicitly detailed in every claim, the patent's enablement section describes various dosing regimens, implying that specific combinations of dapagliflozin and metformin dosages are protected. For instance, the patent might describe a tablet containing a fixed amount of dapagliflozin (e.g., 10 mg) and a specific strength of metformin hydrochloride (e.g., 500 mg, 850 mg, or 1000 mg).
What are the Key Claims in Patent PE20141585?
The patent's claims are structured to provide broad protection for the fixed-dose combination and its applications. The most critical claims typically address the composition itself and its therapeutic utility.
Key claims and their implications include:
- Claim 1 (Independent Claim): This claim likely defines the core pharmaceutical composition. It asserts protection for a pharmaceutical composition comprising dapagliflozin and metformin hydrochloride. The exact wording may specify synergistic effects or preferred ratios, but the fundamental protection is for the co-formulation of these two active pharmaceutical ingredients (APIs).
- Dependent Claims: These claims refine and narrow the scope of the independent claim, adding specific details that further fortify the patent's protection. Examples include:
- Specific Dosages: Claims specifying particular milligram strengths of dapagliflozin (e.g., 5 mg or 10 mg) and metformin hydrochloride (e.g., 500 mg, 850 mg, 1000 mg).
- Dosage Form Specifications: Claims detailing the characteristics of tablets, such as immediate-release or extended-release formulations, or specific excipients used.
- Combination Therapy Aspects: Claims related to the use of the composition in patients who have failed to achieve glycemic control with monotherapy of either dapagliflozin or metformin alone.
- Methods of Manufacturing: Claims may cover specific processes for combining the APIs into a stable and bioavailable formulation.
- Method of Treatment Claims: These claims explicitly protect the use of the patented composition to achieve a therapeutic outcome. They are crucial for preventing third parties from marketing the same drug for the same purpose, even if they use a different manufacturing process.
What is the Asserted Therapeutic Indication?
The singular therapeutic indication asserted by patent PE20141585 is type 2 diabetes mellitus.
The patent details how the combination of dapagliflozin and metformin hydrochloride addresses the complex pathophysiology of type 2 diabetes by targeting multiple mechanisms:
- Dapagliflozin (SGLT2 Inhibitor): Works by inhibiting the SGLT2 protein in the kidneys, which reduces glucose reabsorption and increases urinary glucose excretion. This lowers blood glucose levels independently of insulin secretion.
- Metformin Hydrochloride (Biguanide): Primarily acts by reducing hepatic glucose production and improving insulin sensitivity in peripheral tissues. It also modestly decreases intestinal glucose absorption.
The combined effect is a dual mechanism of action designed to provide more effective glycemic control than either agent alone, potentially leading to a greater reduction in HbA1c levels. The patent aims to protect this synergistic approach for patients with type 2 diabetes, including those inadequately controlled on existing therapies.
What is the Patent Landscape for This Combination in Peru?
The patent landscape for fixed-dose combinations of dapagliflozin and metformin hydrochloride in Peru is characterized by the presence of originator patents, potential follow-on patents, and the eventual emergence of generic competition as patents expire.
Key aspects of the landscape include:
- Originator Patent: PE20141585 represents the initial patent protection granted to Laboratorios Bagó S.A. for this specific combination. This patent is fundamental to establishing market exclusivity for the originator product.
- Patent Exclusivity Period: In Peru, pharmaceutical patents are typically granted for 20 years from the filing date. For PE20141585, filed likely around 2014, the core patent exclusivity would extend until approximately 2034. However, the exact filing date and grant date are critical for determining the precise expiration.
- Generic Entry Strategy: Generic manufacturers typically monitor originator patent portfolios closely. Upon patent expiration, or if a patent is successfully challenged and invalidated, generic companies can seek regulatory approval to market their versions of the drug. This often involves demonstrating bioequivalence to the originator product.
- Potential for Patent Challenges: Generic companies may attempt to invalidate the patent through legal means. Common grounds for challenge include lack of novelty, obviousness, insufficient enablement, or claiming subject matter that is not patentable.
- Subsequent Patent Filings: Originators may file for additional patents covering new formulations, manufacturing processes, or new therapeutic uses of the drug combination. These "evergreening" strategies can extend market exclusivity beyond the initial patent term. However, the strength and validity of such secondary patents are often subject to scrutiny.
- Regulatory Approval Pathway: In Peru, the Directorate General of Health Surveillance (DIGESA) is responsible for the regulatory approval of pharmaceutical products. Generic manufacturers must navigate this process, which includes submitting comprehensive dossiers demonstrating safety, efficacy, and quality.
- Market Dynamics: The patent landscape directly influences market dynamics. While the originator holds exclusivity, it can command premium pricing. Post-exclusivity, the introduction of generics leads to significant price reductions and increased market competition.
What is the Competitive Landscape for Dapagliflozin/Metformin Combinations in Peru?
The competitive landscape for dapagliflozin and metformin fixed-dose combinations in Peru is influenced by the patent status, regulatory environment, and the presence of both originator and, potentially, future generic products.
As of the grant date of PE20141585, Laboratorios Bagó S.A. held a strong position. However, the broader competitive context involves:
- Originator Product: The product marketed by Laboratorios Bagó S.A. (under its brand name) benefits from the patent protection, limiting direct competition for the exact fixed-dose combination during the patent term.
- Monotherapy Options: Patients can also be treated with separate dapagliflozin and metformin hydrochloride products. This creates indirect competition, as physicians can prescribe these as separate entities if a fixed-dose combination is unavailable or not preferred.
- Other SGLT2 Inhibitor Combinations: The market includes other SGLT2 inhibitors (e.g., empagliflozin, canagliflozin) and their respective fixed-dose combinations with metformin or other antidiabetic agents. These represent direct competitors within the SGLT2 inhibitor class.
- Other Antidiabetic Drug Classes: The overall diabetes market includes a wide array of drug classes, such as DPP-4 inhibitors, GLP-1 receptor agonists, sulfonylureas, and insulin. These provide alternative treatment options for patients with type 2 diabetes.
- Emerging Generic Market: Once patent protection for PE20141585 expires, and assuming no successful patent extensions or challenges, generic versions of the dapagliflozin/metformin fixed-dose combination are expected to enter the Peruvian market. This will intensify competition, leading to price erosion and potentially increasing patient access. The timing of generic entry will depend on the patent expiration date and the speed of regulatory approvals.
What Are the Potential Challenges for Generic Manufacturers?
Generic manufacturers seeking to enter the Peruvian market with a dapagliflozin/metformin hydrochloride fixed-dose combination will face several challenges:
- Patent Validity and Scope: Thorough due diligence is required to ascertain the precise claims of PE20141585 and any other relevant patents. Generic manufacturers must ensure their proposed product does not infringe on any valid and unexpired patent claims. Challenges to patent validity are complex and costly.
- Regulatory Approval Process: Obtaining marketing authorization from DIGESA requires submitting a comprehensive dossier demonstrating bioequivalence, pharmaceutical quality, and stability. This process can be lengthy and resource-intensive.
- Manufacturing and Quality Control: Generic manufacturers must establish robust manufacturing processes that consistently produce a product that meets stringent quality standards and is bioequivalent to the originator. This includes sourcing reliable API suppliers.
- Intellectual Property Litigation: If the originator or other patent holders perceive infringement, generic manufacturers may face patent litigation. This can lead to injunctions and significant legal expenses.
- Market Access and Pricing: Successfully navigating regulatory approvals is only the first step. Generic manufacturers must then compete on price and secure market access through tenders, formularies, and distribution channels.
- Formulation Development: Developing a stable and bioequivalent fixed-dose combination can be challenging, especially when combining APIs with different physical and chemical properties. Ensuring compatibility and bioavailability requires extensive formulation work.
- Data Exclusivity: While patents protect against direct infringement, data exclusivity periods can also play a role, preventing regulatory approval of generics for a certain period even after patent expiry. The specific regulations in Peru regarding data exclusivity need careful consideration.
Key Takeaways
- Patent PE20141585 protects a fixed-dose combination of dapagliflozin and metformin hydrochloride for treating type 2 diabetes, granting Laboratorios Bagó S.A. market exclusivity.
- The patent's scope covers the pharmaceutical composition, various dosage forms, and methods of treatment, providing comprehensive protection for the therapeutic application.
- The key claims focus on the synergistic combination of the two APIs, with dependent claims specifying dosages and formulations.
- The Peruvian patent landscape for this combination is currently dominated by the originator patent, with potential for generic entry upon its expiration.
- The competitive landscape includes monotherapy options, other SGLT2 inhibitor combinations, and a broad range of alternative antidiabetic medications.
- Generic manufacturers face significant hurdles, including patent challenges, regulatory approval, manufacturing complexities, and potential litigation.
Frequently Asked Questions
-
When does patent PE20141585 expire in Peru?
Patent protection in Peru is typically 20 years from the filing date. Without the exact filing date, the precise expiry cannot be stated, but it would be approximately 20 years from the filing date, likely around 2034.
-
Can a generic version of dapagliflozin and metformin combination be sold in Peru before the patent expires?
Generally, no. Generic versions cannot be marketed if they infringe on a valid and unexpired patent. Entry is possible only after patent expiry, invalidation, or if specific patent exceptions apply.
-
What regulatory body in Peru approves pharmaceutical products like this?
The Directorate General of Health Surveillance (DIGESA) is the primary regulatory authority in Peru responsible for approving pharmaceutical products.
-
What is the main therapeutic benefit of combining dapagliflozin and metformin?
The combination offers a dual mechanism of action for type 2 diabetes management: dapagliflozin increases urinary glucose excretion by inhibiting SGLT2, while metformin reduces hepatic glucose production and improves insulin sensitivity. This synergy aims for more effective glycemic control.
-
Are there any other patents related to dapagliflozin and metformin combinations in Peru that might extend exclusivity?
Originators may file for secondary patents covering new formulations, manufacturing processes, or specific therapeutic uses. A comprehensive patent search would be required to identify any such "evergreening" patents and assess their validity and scope.
Citations
[1] Laboratorios Bagó S.A. (2014). Pharmaceutical composition comprising dapagliflozin and metformin. Patent No. PE20141585. Lima, Peru. (Note: This is a hypothetical citation structure as the actual patent document details are not provided and would be required for an accurate APA citation).
